{"product_id":"mk-2866-s-4-ac-262","title":"MK-2866 + S-4 \u003c\/br\u003e+ AC-262","description":"\u003ch2\u003e\u003cspan\u003eMK-2866 (Ostarine) + S-4 (Andarine) + AC-262 (Accadrine) | SARMs Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eComplete Recomposition Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Complete Recomposition Research Set combines MK-2866 (Ostarine) 50×15mg, S-4 (Andarine) 50×15mg and AC-262 (Accadrine) 50×15mg, bringing together three non-steroidal selective androgen receptor modulators within one structured laboratory research set. Each compound is supplied as an individually identified 50×15mg capsule product, allowing researchers to investigate three distinct molecules associated with androgen-receptor signalling and tissue-selective pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, commonly known as Ostarine and associated with the developmental name Enobosarm, is one of the better-characterised compounds within SARM research. Its scientific history includes investigation of androgen-receptor activity, tissue-selective signalling and multiple controlled biological endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4, commonly known as Andarine, represents another distinct selective androgen receptor modulator. Its development and experimental history provide a different chemical and pharmacological profile despite sharing the androgen receptor as an important molecular target.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262, also identified in research literature as AC-262,536 and commonly referred to as Accadrine, introduces a third area of selective androgen-receptor investigation. Published research has examined its receptor-binding characteristics, transcriptional activity and partial-agonist behaviour.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Complete Recomposition Research Set therefore provides three different approaches to selective androgen-receptor research rather than simply presenting three interchangeable compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe set name reflects the wider tissue and body-composition-related research themes historically associated with SARM development. It does not establish or guarantee a predetermined experimental result.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eTogether, MK-2866, S-4 and AC-262 create a comparative laboratory framework for examining how structurally different androgen-receptor ligands may generate different receptor, transcriptional and tissue-dependent responses under controlled experimental conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow MK-2866, S-4 and AC-262 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, S-4 and AC-262 share their principal scientific connection through selective androgen-receptor research. The androgen receptor belongs to the nuclear-receptor family and functions as a ligand-responsive transcriptional regulator. When an appropriate molecule interacts with the receptor, changes in receptor conformation and co-regulatory interactions can influence downstream androgen-responsive gene transcription.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe central research question behind selective androgen receptor modulators is not simply whether a compound can interact with the androgen receptor. Researchers have investigated whether structurally different ligands can generate different patterns of receptor activity and tissue-dependent response.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866 provides the most extensively characterised research component of this particular set. Its comparatively developed experimental history makes it useful as a reference point when examining other selective androgen-receptor ligands.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4 provides a second structurally distinct SARM. Its individual pharmacological characteristics allow researchers to compare another androgen-receptor ligand against the Ostarine research framework rather than assuming all compounds within the SARM category behave identically.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262 adds a particularly interesting third comparison because published research has associated it with partial-agonist characteristics. Partial agonism can produce a different maximal receptor response from full agonism under comparable experimental conditions, making receptor activation an important area for comparative investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePlacing the three compounds within one research framework therefore allows researchers to examine receptor interaction, transcriptional signalling and predefined tissue-associated markers across three separate molecules.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination does not establish synergy between MK-2866, S-4 and AC-262. Nor should findings involving one compound automatically be transferred to another.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value instead lies in controlled comparison: three non-steroidal androgen-receptor ligands, three distinct chemical structures and three separate evidence profiles examined within a common selective androgen-receptor research theme.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-2866 (Ostarine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, commonly known as Ostarine and associated with the developmental name Enobosarm, is a synthetic non-steroidal selective androgen receptor modulator with one of the more developed research histories within the SARM category.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts principal molecular target is the androgen receptor. This receptor belongs to the nuclear-receptor superfamily and can influence transcription of androgen-responsive genes following interaction with suitable ligands. The resulting biological response can depend upon receptor expression, cellular environment, co-regulatory proteins, exposure and the experimental endpoint being measured.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearch involving Ostarine has extended beyond early receptor-binding studies into controlled investigation of tissue-related and functional endpoints. This comparatively broad evidence base makes MK-2866 particularly useful when researchers require a recognised SARM against which other androgen-receptor ligands can be compared.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe term selective remains important. Selective androgen receptor modulation does not mean that a compound acts exclusively within one tissue. Rather, SARM research has investigated whether different ligands can generate differing patterns of androgen-receptor-associated activity across experimental tissues and systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Complete Recomposition Research Set, MK-2866 provides the established reference component. Researchers can compare its receptor and tissue-associated profile with S-4 Andarine and AC-262 Accadrine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis comparison is particularly relevant because all three compounds share a broad pharmacological classification while remaining chemically distinct molecules.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe existence of a more developed evidence base also does not mean that every claim associated with Ostarine has been scientifically established. Findings must always be interpreted according to the study design, model, exposure and endpoints used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866 therefore provides a well-characterised foundation for comparative selective androgen-receptor investigation within this three-compound research format.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eS-4 (Andarine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4, commonly known as Andarine, is a synthetic non-steroidal selective androgen receptor modulator developed during research into tissue-selective androgen-receptor pharmacology. It belongs to the genuine SARM research category and provides a second structurally distinct androgen-receptor ligand within the Complete Recomposition Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor acts as a ligand-regulated transcription factor. Interaction with different ligands can alter receptor conformation and influence subsequent interactions with cellular co-regulators and androgen-responsive DNA elements.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis provides an important basis for comparative SARM research. Two compounds interacting with the same receptor do not necessarily generate identical pharmacological profiles or downstream experimental responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4 has been investigated within preclinical selective androgen-receptor research and has contributed to broader understanding of how non-steroidal ligands may produce different patterns of activity across experimental systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin this triple set, Andarine provides an intermediate comparison between MK-2866 and AC-262. Ostarine brings a comparatively developed research history, while AC-262 introduces published interest surrounding partial-agonist characteristics. S-4 contributes another independent non-steroidal androgen-receptor ligand with its own molecular and experimental profile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can therefore examine predefined receptor-associated and tissue-dependent endpoints across all three compounds while maintaining individual controls.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4 should not be treated as interchangeable with Ostarine or AC-262 simply because all three belong to the SARM category. Chemical structure, receptor interaction, concentration, exposure and experimental conditions can materially influence observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts role within the Complete Recomposition Research Set is therefore comparative: providing another recognised selective androgen-receptor research compound against which the characteristics of MK-2866 and AC-262 can be independently evaluated.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eAC-262 (Accadrine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262, commonly known as Accadrine and identified scientifically as AC-262,536, is a synthetic non-steroidal selective androgen receptor modulator investigated through receptor-binding, transcriptional and preclinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eOne of the most interesting aspects of AC-262 research concerns its reported partial-agonist characteristics at the androgen receptor. A partial agonist can interact with a receptor while producing a lower maximal response than a full agonist under comparable experimental conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis makes AC-262 particularly relevant to comparative SARM research because receptor binding alone does not determine the complete experimental response. Ligand structure, receptor conformation, co-regulatory interactions, receptor density and cellular environment can all influence downstream activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePublished AC-262 research has examined androgen-receptor binding and tissue-selective experimental responses, although its evidence base is considerably smaller than that surrounding more extensively investigated compounds such as Ostarine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Complete Recomposition Research Set, this difference becomes useful rather than problematic. MK-2866 provides a comparatively established SARM reference, S-4 provides another recognised non-steroidal androgen-receptor ligand, and AC-262 introduces a molecule particularly associated with partial-agonist research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can therefore investigate whether three structurally different compounds within the same broad pharmacological category produce different receptor-associated and transcriptional observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262 should not be treated as equivalent to either Ostarine or Andarine. Each compound requires independent experimental interpretation and appropriate compound-specific controls.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts inclusion consequently expands the research value of the set beyond simply increasing the number of SARMs being examined. AC-262 adds a distinct pharmacological question concerning receptor activation and partial agonism to the broader selective androgen-receptor research framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring selective androgen receptor modulators from the BioPlex SARMs capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-2688-ostarine-br-50x15mg\" title=\"MK-2866 Ostarine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView MK-2866 Ostarine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"S-4 Andarine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eExplore S-4 Andarine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/ac-262-accadrine-br-50x15mg\" title=\"AC-262 Accadrine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView AC-262 Accadrine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering Ostarine, AC-262, selective androgen-receptor signalling and comparative SARM research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/de\/blogs\/sarms-research-articles-bioplex-peptides-uk\/h1-science-research-studies-ac-262-vs-ostarine-mk-2866-androgen-receptor-research-compared\" title=\"AC-262 vs Ostarine MK-2866 | Androgen Receptor Research | BioPlex Peptides\"\u003e\u003cspan\u003eRead AC-262 vs Ostarine MK-2866: Androgen-Receptor Research Compared ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"MK-2866 S-4 AC-262 SARMs Research Guide | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753551040896,"sku":null,"price":136.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/CompleteRecompositionResearchSet-MK-2866.png?v=1787397834","url":"https:\/\/bioplexpeptides.co.uk\/de\/products\/mk-2866-s-4-ac-262","provider":"BioPlexPeptides.co.uk","version":"1.0","type":"link"}